Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy: A Phase I/II Ascending Multiple Dose Study

NCT04046107 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT04046107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04046107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy: A Phase I/II Ascending Multiple Dose Study
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 1/2
Overall status
Withdrawn
Start date
January 1, 2024
Completion date
September 30, 2027
Enrollment
0 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b virus